Skip to primary navigation
Skip to content
Skip to footer

TVM Capital Life Science Venture Capital

Investing in Life Science Innovation

About Us
- Partners
Team
Senior Advisors
Portfolio
News
Events
Contact

Investing in Life Science Innovation

TVM Capital Life Science is a group of independent investment advisories and fund managers for Venture Capital funds, investing into innovative biotech, pharmaceutical, and medtech companies in Europe, Canada the USA and Asia, with teams based in Munich and Montreal.

Home
About Us
Team
Senior Advisors
Portfolio
News
Events
Contact

Main Content

Lilly to Acquire AurKa Pharma

Lilly to Acquire AurKa Pharma

May 14, 2018

Rapid Micro Biosystems Secures $60 Million In Equity Financing

Rapid Micro Biosystems Secures $60 Million In Equity Financing

May 8, 2018

Deinove To Acquire Biovertis/Morphochem

Deinove To Acquire Biovertis/Morphochem

April 13, 2018

Footer

About Us

We are creating sustainable value – for patients, the pharmaceutical industry and our investors. Since 1984, TVM Capital Life Science has invested in more than 130 life science companies in Europe, Canada and the United States, currently managing in excess of €900 million from more than 50 investors.

Our Team

TVM Capital Life Science operates with an integrated team from its offices in Montreal and Munich. Our mission is to invest in the development of exciting life science products and the growth of substantial companies in the field that are or aspire to be innovative leaders in their market segment.

Offices

TVM Capital GmbH
Munich, Germany

TVM Life Science Management GmbH
Munich, Germany

TVM Life Science Management Inc.
Montreal, Westmount, Canada

li

Copyright © 2018 · TVM Capital Life Science Venture Capital · Privacy Policy · Contact

TVM Capital Group
TVM Capital Healthcare
TVM Capital Life Science

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.